Enhanced Trained Immunity in Peripheral Monocytes in Unstable Angina With Elevated High-Sensitivity C-Reactive Protein

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2025-06-24 DOI:10.1016/j.jacbts.2025.04.014

Jiyu Zhang PhD , Fen Yang MD , Yuhan Liao MD , Xinyi Xia MS , Miao Yu MD, PhD , Desheng Hu MD, PhD , Weimin Wang MD, PhD , Li Zhang MD, PhD , Chaolong Wang PhD , Huirong Liu MD, PhD , Chen Chen MD, PhD , Qing K. Wang PhD , Zhilei Shan PhD , Peter Libby MD, PhD , Xiang Cheng MD, PhD

{"title":"Enhanced Trained Immunity in Peripheral Monocytes in Unstable Angina With Elevated High-Sensitivity C-Reactive Protein","authors":"Jiyu Zhang PhD , Fen Yang MD , Yuhan Liao MD , Xinyi Xia MS , Miao Yu MD, PhD , Desheng Hu MD, PhD , Weimin Wang MD, PhD , Li Zhang MD, PhD , Chaolong Wang PhD , Huirong Liu MD, PhD , Chen Chen MD, PhD , Qing K. Wang PhD , Zhilei Shan PhD , Peter Libby MD, PhD , Xiang Cheng MD, PhD","doi":"10.1016/j.jacbts.2025.04.014","DOIUrl":null,"url":null,"abstract":"<div><div>Despite effective secondary prevention for coronary heart diseases, recurrent events remain high. Elevated high-sensitivity C-reactive protein (hsCRP) indicates increased inflammation risk. This study aimed to investigate the trained immunity of circulating monocytes in unstable angina (UA) patients with elevated hsCRP. We analyzed CD14<sup>+</sup> monocytes from UA patients, comparing high-risk (hsCRP ≥3 mg/L) and low-risk (hsCRP <1 mg/L) groups. We assessed cytokine production and conducted metabolic, transcriptional, and epigenetic profiling. Patients with elevated hsCRP exhibited enhanced proinflammatory responses, glycolytic activity, and altered immune profiles, indicating sustained monocyte trained immunity, which contributes to residual inflammation risk in cardiovascular disease.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 7","pages":"Article 101300"},"PeriodicalIF":8.4000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X25002207","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Despite effective secondary prevention for coronary heart diseases, recurrent events remain high. Elevated high-sensitivity C-reactive protein (hsCRP) indicates increased inflammation risk. This study aimed to investigate the trained immunity of circulating monocytes in unstable angina (UA) patients with elevated hsCRP. We analyzed CD14⁺ monocytes from UA patients, comparing high-risk (hsCRP ≥3 mg/L) and low-risk (hsCRP <1 mg/L) groups. We assessed cytokine production and conducted metabolic, transcriptional, and epigenetic profiling. Patients with elevated hsCRP exhibited enhanced proinflammatory responses, glycolytic activity, and altered immune profiles, indicating sustained monocyte trained immunity, which contributes to residual inflammation risk in cardiovascular disease.

查看原文本刊更多论文

不稳定心绞痛患者外周血单核细胞训练免疫增强伴高敏c反应蛋白升高

尽管对冠心病有有效的二级预防，但复发事件仍然很高。高敏感性c反应蛋白（hsCRP）升高表明炎症风险增加。本研究旨在探讨hsCRP升高的不稳定型心绞痛（UA）患者循环单核细胞的训练免疫。我们分析了UA患者的CD14+单核细胞，比较了高危组（hsCRP≥3mg /L）和低危组（hsCRP < 1mg /L）。我们评估了细胞因子的产生，并进行了代谢、转录和表观遗传分析。hsCRP升高的患者表现出增强的促炎反应、糖酵解活性和改变的免疫谱，表明持续的单核细胞训练免疫，这有助于心血管疾病的残留炎症风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.